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Rat connective tissue mast cells are known to store significant 
amounts of mast cell protease I (RMCP I), which suppresses 
normal cell growth and mediates cytotoxicity against tumor 
cell lines, including the fibrosarcoma cell line FL. To better 
define its effects on FL cells, RMCP I was added to FL cul-
tures for 30 min. Analysis of de novo nuclear protein synthesis 
revealed that RMCP I suppressed the expression of three 
proteins (4 1, 46, and 69 kD) and enhanced the expression of 
two other proteins (25 and 32 kD). Treatment of FL cells 
with diisopropylfluorophosphate (DFP)-inactivated RMCP 
I proved that these effects were largely independent of the 
protease catalytic site. Western blot hybridization, using a 
monoclonal antibody to phosphotyrosine-containing pro-
teins, revealed that RMCP I inhibited phosphorylation of a 
nuclear and a cytoplasmic 81-kD tyrosylprotein. Inhibition of 
R at mast cells are known to produce and store a number of mediators in their cytoplasmic granules [1- 5]. Among these mediators are the serine proteases, rat mast cell protease I (RMCP I), and RMCP II [4] . RMCP I exists in peritoneal and skin mast cells 
whereas RMCP II is localized in mast cells occupying mucosal 
surfaces [3-5]. RMCP I is simi lar to human skin mast cell chymase 
in that both have chymotryptic activites that recognize a specific 
amino acid sequence [3 - 5]. 
Although their biologic functions are unknown, RMCP I and 
human mast cell chymase cleave the epidermis from the dermis and 
convert angiotensin I to angiotensin II [6,7]. In addition, RMCP I 
lyses tumor cells itl vitro including the mouse skin fibrosarcoma line 
FL and may mediate antitumor activity in vivo [8-10]. More recent 
studies indicate that RMCP I at concentrations ranging from 16 to 
127 nM suppresses the growth of normal skin keratinocytes and 
fibroblasts in vitro, * suggesting that RMCP I may be capable of 
affecting normal skin cell functions. As a result of these observa-
tions, we have begun to examine the interaction and metabolic 
effects of RMCP I on cells in vitro. 
MATERIALS AND METHODS 
Materials CNBr-Sepharose and Sephadex G-50 were obtained from 
Pharmacia/LKB, Piscataway, N]; phenylbutylamine, D-tryptophan meth-
ylester, protease substrates, trypsin (type XI), chymotrypsin (type I-S), 
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nuclear tyrosine kinase activity by RMCP I appeared to be 
catalytic site dependent, whereas cytoplasmic tyrosine kinase 
inhibition was independent of RMCP I proteolytic activity. 
Biotinylated RMCP I was used to identify potential surface-
binding proteins. Three specific binding complexes (130, 
150, and 210 kD) were detected. The binding ofbiotinylated 
RMCP I to these surface proteins was inhibited by excess 
unlabeled RMCP I, but not by trypsin or chymotrypsin. We 
speculate that the binding proteins may be critical in initiat-
ing RMCP I-induced metabolic changes on FL cells. The 
ability of RMCP I to alter the metabolism of cells suggests 
that it may have an important role in regulating their func-
tions. Key words: chymase/tyrosine kinase. ] Invest Dermato/ 
103:84-87,1994 
and diisopropylfluorophosphate (DFP) were purchased from Sigma Chemi-
cals Co., St. Louis, MO. 35S-Methionine (> 1000Ci/mMol) was purchased 
from Amersham, Arlington Heights, IL. Hybridoma cell line FB2 was pur-
chased from American Type Culture Collection, Bethesda, MD. N-Hy-
droxysuccinimidobiotin and disuccinimidylsuberate were purchased from 
Pierce, Rockford, IL. Vectastain avidin-biotin-peroxidase (ABC) kit and 
horseradish peroxidase-conjugated avidin were obtained from Vector Labs, 
Burlingame, CA. 
Preparation ofRMCP I RMCP I was purified from rat peritoneal mast 
cells using a procedure modified from the method of Schechter e/ al [5] . 
Purified mast cells at 107 / ml were incubated overnight in buffer containing 
10 mM sodium 3-[N-morpholino)-propanesulfonate (MOPS), pH 6.B. The 
cell lysate was centrifuged at 10,000 X g for 20 min. The pellet was dissolved 
in a buffer (10 mM MOPS, pH 6.B, 2.0 M NaCI) at 4"C, and fractionated 
through a phenylbutylamine-Sepharose affinity column (1.2 X 5 em). 
RMCP I was eluted from the column with a buffer containing 0.2 M D-
tryptophan methyl ester, a competitive inhibitor of chymotrypsin-like pro-
teases, 10 mM MOPS, and 0.4 M NaCI. Eluted fractions containing RMCP 
I were identified by their RMCP I protease activity, then pooled and further 
purified through a Sephadex G-50 chromatography column (0.B5 X 28 
cm). Purified RMCP I was identified by polyacrylamide gel electrophoresis 
and concentrated using a Centricon-l0 (Amicon) in buffer (10 mM MOPS, 
1.0 M NaCI, pH 6.B) and stored at -BO"C. 
The protease activity ofRMCP I was determined using specific substrates 
N-Suc-Ala-Ala-Pro-Phe-p-Nitroanilide for RMCP I, N-CBZ-Gly-Pro· 
Arg-p-Nitroanilide for tryptase, and N-MeO-Suc-Ala-Ala-Pro-Val-p-Ni-
troanilide for elastase [5). Routine protease activities were carried out at 
room temperature in 200 JlI of 0.4 M Tris HCI, 2.0 M NaCI, pH B.O, 
containing 1.0 mM substrate and 10 JlI of the enzyme preparation. Substrate 
hydrolysis was monitored spectrophotometrically at 410 nm at I-min inter-
vals for a total of3 min. Previous studies have demonstrated that RMCP I, at 
concentrations ranging from 127 nM to 16 nM, suppresses the growth of 
normal and tumor cell lines ill vitro, with 127 nM being most cytotoxic'; 
therefore, a concentration of 127 nM RMCP I was used in these studies. 
Covalent inactivation of the RMCP I catalytic site was performed accord· 
ing to the method described by Shick e/ al [11]. RMCP I at 2.5 JlM in 50 JlI of 
1.0 M NaCI, 0.Q1 M MOPS, pH 6.B, was reacted with 1 JlI DFP (0.1 mM) 
at room temperature for 20 min, then filtered with a Centricon-l 0 (Amicon) 
to remove free DFP. DFP-RMCP I activity was monitored spectrophoto-
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metrically using N-Suc-Ala-Ala-Pro-Phe-p-Nitroanilide as a substrate. 
Typically, < 1 % specific of RMCP I activ ity could be detected in the OFP-
RMCP I preparation. 
Biotinylation of RMCP I was performed according to the method of 
Wojchowski et of [12]. RMCP I at 2.5 ,uM in 50 ,Ill of buffer {0.1 M NaCl, 
10 mM MOPS, pH 7.6, was reacted with 2/d of 0.1 M N-hydroxysuccini-
midobiotin in dimethoxysulfoxide at 4°C for 30 min, then conccntratcd in 
buffer (0.1 M NaCI in 10 mM MOPS, pH 6.8) . The resu lting RMCP I 
activity and biotinylation efficiency were mcasured by a protease activity 
assay and Western blot hybridization using unlabeled RMCP I as a control. 
35S_Methionine Labeling and Cell Extract Preparations Itl l/ jtro 35S_ 
methionine labeling assay was performed according to the mcthod of Ceullo 
et af [13]. FL cells (4 X 106 cells/25 cm2 flask) were chilled on ice for 10 min 
and incubated with 127 nM RMCP I or OFP-RMCP I in methionine-free 
RPMI-1640 medium at 4°C for 30 min. Cells incubated with RPMI-1640 
medium alone were used as untreated controls. The cells were washed thor-
oughly and incubatcd in RPMI-1640 medium with 10% dialyzed serum in 
the presence of 0.1 mCi/ ml of 35S-methionine for 30 min, then harvested 
and lysed in a Tris buffer (20 mM, pH 7.6) containing 1 % Nonidet P40, 
2 mM phenylmethyl5ulfonylfluoride, 0.1 mM benzamidinc, 5 ,ug/ ml apro-
tinin, 10 ,ug/mlleupetin, ethylenediamine tetraacetic acid (EOTA), on ice 
for 10 min. The celllysates were centrifuged at 10,000 X g for 20 min and 
the supernatants were aspirated as cytoplasmic extracts. Cell pellets were 
dissolved in 20 nLM Tris, pH 7.2, containing 1 % sodium dodecyl sulfate 
(SDS) and 2 mM B-mercaptoethanol. After clarifying by centrifugation, the 
supernatants were used as nuclear extracts. 
polyacrylamide Gel Electrophoresis To assess de I/OVO protein synthe-
sis, an aliquot of200,OOO counts per minute (cpm) from each protein extract 
was denatured at 95 °C for 5 min and analyzed on an SOS-polyacrylamide 
gel according to the procedure of Laemmli [1 4]. Prestained molecular-
weight standards were included in each gel. The gel was fixed with 10% 
trichloroacetic acid, stained with Brilliant Blue R, heat-dried, and exposed to 
X-ray film. After autoradiography, the de 'IOVO protein synthesis were identi-
fied from the images on the X-ray film . 
Western Blot Hybridization Mouse monoclonal antibody (MoAb) 
(IgG3) to phosphotyrosine-containing proteins was prepared from hybri-
doma cell line FB2 [15]. The specific activity of the antibody in culture 
medium was examined by a slot blot hybridization using O-phospho-L-tyr-
osine and L-ryrosine as targets. 
Western blot hybridization was performed according to the method of 
Burnette [16]. An aliquot of 500,000 cpm from each cell extract was ana-
lyzed by SOS polyacrylamide gel, then electroblotted onto a nitrocellulose 
filter. The filter was blocked with 7% nonfat milk in a Tris-buffered saline 
solution buffer containing 20 mM Tris, pH 7.6, 100 nLM NaCl, and 1% 
Tween-20 for 2 h, then hybridized with the FB2 MoAb in TBSS at 4°C 
overnight. After washing with TBSS three times for 30 min, the MoAb-
binding proteins on the filters were detected by a Vectastain avidin-biotin-
peroxidase complex (ABC) kit, using avidin and biotinylated alkaline phos-
phatase as a reporter and p-nitrophenylphosphate as a substrate. 
Competitive Inhibition Assay Competitive inhibition assay was per-
formed according to the method of Oesiel and Mau [17] . FL cells at 90% 
confluence were washed with ice-cold phosphate-buffered saline (PBS) 
twice for 5 min, then incubated with 127 ILM biotinylatcd RMCP I with or 
without fivefold excess proteolytic activiry of unlabeled RMCP I, chymo-
trypsin, or trypsin at 4°C for 30 min. Thc protcolytic activities of RMCP I, 
chymotrypsin, and trypsin were measured according to the method of 
Plantner [18], using azoalbumin as a substratc. After incubation, the cells 
were rinsed twice with ice-cold PBS and reacted with cross-lilLking agent 
disuccinimidyl suberate (I mM) in PBS for 20 min at room temperature, 
washed twice with PBS, and lysed in 20 mM Tris, pH 7.4, containing 1 % 
Triton X-114 containing 2 mM phenylmcthylsulfonylfloride, 0.1 rnM 
benzamidine, 5 ,ug/rnl aprotinin, 10 ,ug/mllcupetin, and 0.2 mM EOTA on 
ice for 10 min. The cell lysates were desa lted using a P-l 0 Bio-Gel column 
and resolved on an SOS polyacrylamide gel. Prestained protein markers and 
biotinylated RMCP I werc included in each gel. Cell proteins were elcctro-
blotted from the gel onto a nitrocellulose filter. Thc filter was treated with 
7% non-fat milk in TBSS and hybridized with HRP-avidin in TBSS for 45 
min. After washing twice for 30 min in TBSS at room tcmperature, the filter 
was reacted with 1 % l,4-diaminobenzidinc tetrahydrochloride in 100 nLM 
Tris-HCI, pH 7.6, containing 1 % NiCI2 • 
RESULTS 
Effects of RMCP I on Cell Protein Synthesis The ability of 
RMCP I to alter protein synthcsis was investigated by incubating FL 
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Figure 1. RMCP I suppressed the synthesis of three nuclear proteins (41, 
46, and 69 kD) and enhanced the expression of two othcr proteins (25 and 32 
kO) in FL cells. FL cells were treatcd without RMCP I (fa lie 0) , with RMCP 
I (fOlie b) , or OFP-inactivated RMCP I (Ialle c), then pause-labeled with 
35S-methionine at 37"C for 30 min. The nuclear extracts were analyzed 
through a 7 - 14% polyacrylamide gradIent gel and au toradiography. 
tumor cells with RMCP I (127 nM) at 4 °C for 30 min. D e 110110 
protein synthesis was monitored by a 35S-methionine labeling assay 
and polyacrylamide gel electrophoresis. Comparison of nuclear ex-
tracts from RMCP I-treated and untreated cel ls revealed that the 
synthesis of three proteins (41, 46, and 69 kD) were decreased and 
the cxpression of two other proteins (25 and 32 kD) was enhanced 
(Fig 1). There were no changes in cytoplasmic proteins observed 
after FL cell incubations with RMCP I (data not shown). 
. To be.tter define the mech~nism of RMCP I action, its catalytic 
site was macttvated by the senne protease inhibitor DFP, and de 110 110 
protein synthesis in FL cells was examined. FL cells were incubated 
with DFP-RMCP I under culture conditions identical to those for 
active enzyme. Figure 1 demonstrates that DFP-RMCP I also sup-
pressed the .synthesls of the 41-, 46-, and 69-kD proteins, as well as 
the expreSSlon of two (25- and 32-kD) proteins. 
Effect of RMCP I on Protein Tyrosine Kinase Activities 
Because tyrosine kinases appear to play an important role in cell 
growth [19-24], the effect ofRMCP I on nuclear and cytoplasmic 
tyrosine kinases in FL cells was investiga ted by monitoring tyrosyl-
protein phosphorylation . FL cells were incubated with RMCP I 
(1?7 ~1M) or buffer control at 4 °C for 30 min . Phosphotyrosylpro-
tems m cytoplasmIC and nuclear extracts were identified by W estern 
blot hybridization using FB2 MoAb. Figurc 2 demonstrates that 
FB2 recognizes a nuclear and cytoplasmic 81-kD protein, and thus 
it appears that RMCP I inhibits the phosphoryl ation of these pro-
teins in the cytoplasm and nucleus. 
FL cells were treated under the samc experimental conditions as 
DFP-RMCP 1. In the prese nce of DFP-RMCP I, phosphorylation 
of the cytoplasmic 81 -kD protein was inhibited, whereas phospho-
ry latio n of the 81-kD nuclear protein occurred (Fig 2). 
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Figure 2. RMCP I inl1ibited the phosphorylation of an 81-kD tyrosine-
containing protein. FL cells were treated with no RMCP I (la/Jes a and d), 
RMCP I (la/Jes b and e), and DFP-inactivated RMCP I (lalJes [and J). Nucl ear 
(lanes a, h, and e) and cytoplasmic (lan es d, e, and J) extracts were analyzed by 
Western blot hybridization using a MoAb to phosphoryltyrosine-contain-
ing proteins as the primary antibody and a Vectastain ABC kit as the detec-
tion reagents, as described in Materials alJd Methods. 
RMCP I-Specific Binding Proteins Incubation of FL cells 
w ith biotinylated RMCP I revealed three surface-binding proteins 
with combined RMCP I-binding protein molecular weights of 130, 
150, and 210 kD (Fig 3, lane a). A competitive inhibition assay was 
used to prove the specificity ofRMCP I binding to these proteins on 
FL cells. In the presence of a fivefold excess of unlabeled RMCP I, 
but not excess chymotrypsin or trypsin, binding of biotinylated 
RMCP I to these surface proteins was inhibited (Fig 3, lalles c,d,e), 
thus demonstrating that they are RMCP I-specific. These same 
proteins also were identified with DFP-RMCP I, indicating that the 
interaction of RMCP I with these proteins was independent of its 
catalytic site (Fig 3, lane b) . 
DISCUSSION 
The results of this study demonstrate that RMCP I alters the metab-
olism of FL cell s. In 35S-methionine labeling experiments, RMCP I 
specifically altered the expression of five different nuclear proteins. 
The synthesis of three nuclear proteins was decreased after FL cell 
exposure to RMCP I, whereas two others were enhanced. Western 
blot analysis demonstrated that RMCP I also inhibited both nuclear 
and cytoplasmic tyrosine kinases that specifically phosphorylated 
tyrosylproteins with a molecular weight of 81 kD. 
Experiments using DFP-inactivated RMCP I showed that the 
catalytic site of this enzyme is not essential for all of its effects on FL 
cells. Both RMCP I and DFP-inactivated RMCP I altered new 
protein synthesis as well as inhibited the phosphorylation of the 
81-kD protein in the cytoplasm. On the other hand, the catalytic 
site of RMCP I was essential for affecting nuclear tyrosine kinase 
activity because DFP-RMCP I did not block the phosphorylation of 
the 81-kD nuclear protein. Thus, from these observations it appears 
that both the catalytic and noncatalytic sites of RMCP I are impor-
tant for inducing changes in FL cell metabolism. 
FL cell s appear to express three specific proteins for RMCP I. The 
specificity of the RMCP I interaction with these proteins was con-
firmed by the finding that excess unlabeled RMCP I, but not chy-
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motrypsin or trypsin, blocked its binding to all three proteins. Be-
cause RMCP I and DFP-RMCP I bind to surface proteins and 
induce metabolic changes, it is likely that the interaction of this 
protease with these proteins involves both the catalytic and a nonca-
talytic(s) site . Because cell surface proteins are essential elements in 
signal transduction, we speculate that the binding of RMCP I to 
surface proteins is critical for initiating its effects on FL cell s. 
Previous experiments have shown that RMCP I at concentrations 
ranging from 16 11M to 127 nM suppress growth and induce cyto-
toxicity in vitro against a number of cell lines (submitted for publica-
tion). In this study, 127 nM RMCP I was chosen for investigation 
because it induced the most dramatic effect on cell viability and 
therefore was most likely to affect FL cell metabolism. Although 
the physiologic significance of this protease concentration is un-
known, it is conceivable that when released from mast cells, similar 
levels ofRMCP I can be achieved locally in tissues. Furthermore, in 
these experiments FL cells were incubated with RMCP I for on ly 30 
min, w hereas it is quite feasibl e that cell s may be exposed to this 
enzyme for greater lengths of time in "ivo. 
Some of the findings in this study suggest that a correlation may 
exist between the observed metabolic changes in cells and RMCP 
I-induced cytotoxicity. Results from our laboratory demonstrate 
that RMCP I kills tumor cells, whereas DFP-RMCP I has no cyto-
toxic effect (submitted for publication). In addition, RMCP I inhib-
its nuclear tyrosine kinase activity in FL cells, and tyrosine kinases 
are vital for cell growth [22,24]. Conversely, DFP-inactivated 
(noncytotoxic) RMCP I was capab le of binding to cell-surface pro-
teins and inducing several metabolic changes. Therefore, whereas 
these results indicate that RMCP I affects FL cell metabolism, it 
appears that only some of the observed metabolic alterations are 
linked to cell death. 
At present, it is not certain whether the 81-kD proteins observed 
in both the nucleus and cytoplasm of FL cells are identical or repre-
sent two different proteins. Although phosphotyrosylproteins are 
rare in normal cells, they are common in neoplastic cells, and often 
a b C d e f 9 (Kd) 
-170 
-116 
-85.2 
-55.6 
-39.2 
-26.6 
Figutc J. Detection of cell-surface RMCP I-specific binding proteins. FL 
cells were incllbated with hiotinylated RMCP I (Ialle aJ, biotinylated DFP-
RMCP I (laue bJ , biotinylated RMCP I with fivefold unlabeled RMCP ) 
(Iarte eJ, biotinylated RMCP I with fivefold unlabeled chymotrypsin (la/Ie d), 
and biotinylated RMCP I with fivefold llnlabeled trypsin (larte eJ at 4·C for 
20 min, then cross-linked with DSS at room temperature for 20 min. Cyto-
plasmic membrane proteins, moleclllar weight markers (larte f), and hiotin-
ylated RMCP I (Ialle g) were ana lyzed by Western blot hybridization. 
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are linked to signal transduction, cell metabolism, and oncogenesis 
[19-24]. Though the function of the 81 kD tyrosylprotein{s) is 
unknown, it may serve a critical role in RMCP I-mediated suppres-
sion of cell growth, and studies are in progress to investigate the 
importance of this protein for cell survival. 
We wish to thank Dr. N orman Schechter f or providing the RMCP I purification 
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